CNTA Centessa Pharmaceuticals | $39.69
-0.2% | 8/15/2023 | | Boost Price Target | $6.00 ➝ $11.00 | Outperform | 00.00% | View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 8/15/2023 |
CYTK Cytokinetics | $67.07
-2.0% | 8/15/2023 | | Initiated Coverage | $58.00 | Outperform | 00.00% | View details for SVB Securities rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
DMRA Damora Therapeutics, Inc. Common Stock | $20.15
-3.9% | 8/15/2023 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) on 8/15/2023 |
DSGN Design Therapeutics | $10.66
+1.0% | 8/15/2023 | | Downgrade | $6.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
EXEL Exelixis | $52.58
-0.8% | 8/8/2023 | | Initiated Coverage | $18.00 | Market Perform | 00.00% | View details for SVB Securities rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $27.60
-1.7% | 8/8/2023 | | Initiated Coverage | $33.00 | Outperform | 00.00% | View details for SVB Securities rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
NUVL Nuvalent | $123.35
+0.1% | 8/8/2023 | | Initiated Coverage | $42.00 | Market Perform | 00.00% | View details for SVB Securities rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
QTRX Quanterix | $3.07
-0.6% | 8/8/2023 | | Upgrade | $30.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
RLAY Relay Therapeutics | $13.49
-4.3% | 8/8/2023 | | Initiated Coverage | | Outperform | 00.00% | View details for SVB Securities rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NVCR NovoCure | $16.65
-3.4% | 8/4/2023 | | Initiated Coverage | $51.00 | Outperform | 00.00% | View details for SVB Securities rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
BLTE Belite Bio | $136.62
-3.4% | 7/26/2023 | | Initiated Coverage | $25.00 | Outperform | 00.00% | View details for SVB Securities rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
NBIX Neurocrine Biosciences | $160.86
-2.7% | 7/24/2023 | | Upgrade | $115.00 ➝ $125.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX CryoPort | $14.77
-2.8% | 7/13/2023 | | Downgrade | $30.00 ➝ $10.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of CryoPort (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol Myers Squibb | $55.62
-1.5% | 7/10/2023 | | Initiated Coverage | $66.00 | Market Perform | 00.00% | View details for SVB Securities rating of Bristol Myers Squibb (NYSE:BMY) on 7/10/2023 |
MLTX MoonLake Immunotherapeutics | $17.49
-1.7% | 6/26/2023 | | Boost Price Target | $28.00 ➝ $56.00 | | 00.00% | View details for SVB Securities rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 6/26/2023 |
PEPG PepGen | $1.38
| 6/14/2023 | | Lower Price Target | $33.00 ➝ $28.00 | | 00.00% | View details for SVB Securities rating of PepGen (NASDAQ:PEPG) on 6/14/2023 |
UNH UnitedHealth Group | $407.80
-1.3% | 6/14/2023 | | Lower Price Target | $625.00 ➝ $560.00 | | 00.00% | View details for SVB Securities rating of UnitedHealth Group (NYSE:UNH) on 6/14/2023 |
OCS Oculis | $10.97
-0.1% | 6/12/2023 | | Initiated Coverage | | Outperform | 00.00% | View details for SVB Securities rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
CVAC CureVac | $4.66
| 6/8/2023 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for SVB Securities rating of CureVac (NASDAQ:CVAC) on 6/8/2023 |
CSTL Castle Biosciences | $21.08
| 6/5/2023 | | Lower Price Target | $50.00 ➝ $35.00 | | 00.00% | View details for SVB Securities rating of Castle Biosciences (NASDAQ:CSTL) on 6/5/2023 |
UHS Universal Health Services | $144.66
-1.3% | 5/26/2023 | | Upgrade | $147.00 ➝ $170.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Universal Health Services (NYSE:UHS) on 5/26/2023 |
A Agilent Technologies | $131.88
-2.7% | 5/24/2023 | | Lower Price Target | $170.00 ➝ $145.00 | Outperform | 00.00% | View details for SVB Securities rating of Agilent Technologies (NYSE:A) on 5/24/2023 |
ARWR Arrowhead Pharmaceuticals | $70.73
-3.5% | 5/12/2023 | | Downgrade | $40.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
ABCL AbCellera Biologics | $5.09
-4.0% | 5/5/2023 | | Lower Price Target | $16.00 ➝ $15.00 | | 00.00% | View details for SVB Securities rating of AbCellera Biologics (NASDAQ:ABCL) on 5/5/2023 |
AGIO Agios Pharmaceuticals | $28.88
+2.6% | 5/5/2023 | | Lower Price Target | $37.00 ➝ $34.00 | | 00.00% | View details for SVB Securities rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 5/5/2023 |
ALHC Alignment Healthcare | $20.56
+7.1% | 5/5/2023 | | Lower Price Target | $24.00 ➝ $12.00 | | 00.00% | View details for SVB Securities rating of Alignment Healthcare (NASDAQ:ALHC) on 5/5/2023 |
LNTH Lantheus | $100.24
+0.3% | 5/5/2023 | | Boost Price Target | $120.00 ➝ $127.00 | | 00.00% | View details for SVB Securities rating of Lantheus (NASDAQ:LNTH) on 5/5/2023 |
PRVA Privia Health Group | $22.90
+3.3% | 5/5/2023 | | Boost Price Target | $39.00 ➝ $40.00 | | 00.00% | View details for SVB Securities rating of Privia Health Group (NASDAQ:PRVA) on 5/5/2023 |
REGN Regeneron Pharmaceuticals | $601.65
-2.4% | 5/5/2023 | | Lower Price Target | $976.00 ➝ $895.00 | | 00.00% | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/5/2023 |
VIR Vir Biotechnology | $8.25
-3.1% | 5/5/2023 | | Lower Price Target | $43.00 ➝ $42.00 | | 00.00% | View details for SVB Securities rating of Vir Biotechnology (NASDAQ:VIR) on 5/5/2023 |
DHR Danaher | $183.88
-2.4% | 5/1/2023 | | Initiated Coverage | $300.00 | Outperform | 00.00% | View details for SVB Securities rating of Danaher (NYSE:DHR) on 5/1/2023 |
LLY Eli Lilly and Company | $1,138.78
-0.5% | 5/1/2023 | | Boost Price Target | $410.00 ➝ $458.00 | | 00.00% | View details for SVB Securities rating of Eli Lilly and Company (NYSE:LLY) on 5/1/2023 |
HUM Humana | $365.89
+0.7% | 4/27/2023 | | Lower Price Target | $640.00 ➝ $600.00 | | 00.00% | View details for SVB Securities rating of Humana (NYSE:HUM) on 4/27/2023 |
ALVR AlloVir | $4.09
-2.0% | 4/26/2023 | | Boost Price Target | $368.00 ➝ $437.00 | | 00.00% | View details for SVB Securities rating of AlloVir (NASDAQ:ALVR) on 4/26/2023 |
PRTA Prothena | $7.91
-6.6% | 4/24/2023 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for SVB Securities rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
BBIO BridgeBio Pharma | $67.40
-0.4% | 4/13/2023 | | Boost Price Target | $25.00 ➝ $27.00 | Outperform | 00.00% | View details for SVB Securities rating of BridgeBio Pharma (NASDAQ:BBIO) on 4/13/2023 |
FDMT 4D Molecular Therapeutics | $8.72
-5.5% | 4/13/2023 | | Lower Price Target | $14.00 ➝ $13.00 | Market Perform | 00.00% | View details for SVB Securities rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 4/13/2023 |
ARWR Arrowhead Pharmaceuticals | $70.73
-3.5% | 4/12/2023 | | Upgrade | $21.00 ➝ $35.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $78.12
+0.8% | 4/11/2023 | | Initiated Coverage | $25.00 | Market Perform | 00.00% | View details for SVB Securities rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
IPHA Innate Pharma | $1.75
-1.1% | 4/10/2023 | | Boost Price Target | $9.00 ➝ $10.00 | | 00.00% | View details for SVB Securities rating of Innate Pharma (NASDAQ:IPHA) on 4/10/2023 |
Musk is burning $2.5 billion a quarter on AI. One company holds the key. (Ad) SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware.
Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost. Read the S-1 breakdown and get the company name free |
REGN Regeneron Pharmaceuticals | $601.65
-2.4% | 3/27/2023 | | Upgrade | $834.00 ➝ $976.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
INCY Incyte | $105.39
+2.1% | 3/24/2023 | | Upgrade | $61.00 | Underperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Incyte (NASDAQ:INCY) on 3/24/2023 |
RAIN Rain Enhancement Technologies Holdco | $2.01
-3.8% | 3/21/2023 | | Initiated Coverage | $11.00 | Outperform | 00.00% | View details for SVB Securities rating of Rain Enhancement Technologies Holdco (NASDAQ:RAIN) on 3/21/2023 |
CNTA Centessa Pharmaceuticals | $39.69
-0.2% | 3/17/2023 | | Initiated Coverage | $6.00 | Outperform | 00.00% | View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
PTCT PTC Therapeutics | $73.35
-0.4% | 3/17/2023 | | Initiated Coverage | $48.00 | Market Perform | 00.00% | View details for SVB Securities rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
HALO Halozyme Therapeutics | $70.50
-1.4% | 3/16/2023 | | Downgrade | $42.00 | Outperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
FULC Fulcrum Therapeutics | $3.51
-0.3% | 3/10/2023 | | Lower Price Target | $18.00 ➝ $10.00 | | 00.00% | View details for SVB Securities rating of Fulcrum Therapeutics (NASDAQ:FULC) on 3/10/2023 |
ARGX argenex | $862.18
-2.5% | 3/3/2023 | | Boost Price Target | $430.00 ➝ $435.00 | | 00.00% | View details for SVB Securities rating of argenex (NASDAQ:ARGX) on 3/3/2023 |
AHCO AdaptHealth | $9.93
+1.2% | 3/1/2023 | | Lower Price Target | $30.00 ➝ $23.00 | | 00.00% | View details for SVB Securities rating of AdaptHealth (NASDAQ:AHCO) on 3/1/2023 |
MDRX Veradigm | $5.10
| 3/1/2023 | | Lower Price Target | $24.00 ➝ $17.00 | | 00.00% | View details for SVB Securities rating of Veradigm (NASDAQ:MDRX) on 3/1/2023 |
GPCR Structure Therapeutics | $41.53
+0.7% | 2/28/2023 | | Initiated Coverage | $33.00 | Outperform | 00.00% | View details for SVB Securities rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
IRON Disc Medicine | $67.25
-1.6% | 2/28/2023 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for SVB Securities rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
MRNA Moderna | $45.99
-3.6% | 2/24/2023 | | Downgrade | $111.00 ➝ $93.00 | Market Perform ➝ Underperform | 00.00% | View details for SVB Securities rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
NKTR Nektar Therapeutics | $56.78
+1.0% | 2/24/2023 | | Lower Price Target | $75.00 ➝ $45.00 | | 00.00% | View details for SVB Securities rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $73.32
-1.7% | 2/23/2023 | | Lower Price Target | $34.00 ➝ $27.00 | | 00.00% | View details for SVB Securities rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $7.10
+2.4% | 2/23/2023 | | Upgrade | $34.00 | Market Perform ➝ Outperform | 00.00% | View details for SVB Securities rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $225.16
-0.1% | 2/10/2023 | | Upgrade | $135.00 ➝ $153.00 | Underperform ➝ Market Perform | 00.00% | View details for SVB Securities rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
CI Cigna Group | $296.34
+0.5% | 2/8/2023 | | Lower Price Target | $335.00 ➝ $309.00 | | 00.00% | View details for SVB Securities rating of Cigna Group (NYSE:CI) on 2/8/2023 |
VRTX Vertex Pharmaceuticals | $435.71
-2.3% | 2/8/2023 | | Lower Price Target | $374.00 ➝ $365.00 | | 00.00% | View details for SVB Securities rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
AMGN Amgen | $337.73
-2.0% | 2/2/2023 | | Lower Price Target | $282.00 ➝ $267.00 | | 00.00% | View details for SVB Securities rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
META Meta Platforms | $570.98
-2.3% | 2/2/2023 | | Boost Price Target | $220.00 ➝ $255.00 | Outperform | 00.00% | View details for SVB Securities rating of Meta Platforms (NASDAQ:META) on 2/2/2023 |
DNLI Denali Therapeutics | $20.61
-0.9% | 1/30/2023 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for SVB Securities rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023 |
BHVN Biohaven | $11.12
+0.3% | 1/24/2023 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for SVB Securities rating of Biohaven (NYSE:BHVN) on 1/24/2023 |
